Enhancement of arsenic trioxide cytotoxicity by dietary isothiocyanates in human leukemic cells via a reactive oxygen species-dependent mechanism.

[1]  Yung-Hyun Choi,et al.  Sulforaphane generates reactive oxygen species leading to mitochondrial perturbation for apoptosis in human leukemia U937 cells. , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  Jie Wang,et al.  PML/RARα fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: Mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase , 2008, Journal of cellular physiology.

[3]  E. Ho,et al.  Multi-targeted prevention of cancer by sulforaphane. , 2008, Cancer letters.

[4]  S. Ralph.  Arsenic-Based Antineoplastic Drugs and Their Mechanisms of Action , 2008, Metal-based drugs.

[5]  N. Doudican,et al.  Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism , 2008, Cancer Chemotherapy and Pharmacology.

[6]  P. Adamson,et al.  Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. , 2008, Blood.

[7]  N. Juge,et al.  Molecular basis for chemoprevention by sulforaphane: a comprehensive review , 2007, Cellular and Molecular Life Sciences.

[8]  A. Quintás-Cardama,et al.  Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia? , 2006, Hematological oncology.

[9]  T. Kwon,et al.  Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. , 2006, Cancer research.

[10]  J. Jakubikova,et al.  Isothiocyanates induce cell cycle arrest, apoptosis and mitochondrial potential depolarization in HL-60 and multidrug-resistant cell lines. , 2005, Anticancer research.

[11]  J. Jakubikova,et al.  Role of PI3K/Akt and MEK/ERK signaling pathways in sulforaphane- and erucin-induced phase II enzymes and MRP2 transcription, G2/M arrest and cell death in Caco-2 cells. , 2005, Biochemical pharmacology.

[12]  Simon C Watkins,et al.  Sulforaphane-induced Cell Death in Human Prostate Cancer Cells Is Initiated by Reactive Oxygen Species* , 2005, Journal of Biological Chemistry.

[13]  F. Lo‐Coco,et al.  Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells , 2005, Leukemia.

[14]  S. Waxman,et al.  Glutathione-S-transferase pi inhibits As2O3-induced apoptosis in lymphoma cells: involvement of hydrogen peroxide catabolism. , 2005, Blood.

[15]  D. Neuberg,et al.  Dietary intake of Cruciferous vegetables, Glutathione S-transferase (GST) polymorphisms and lung cancer risk in a Caucasian population , 2004, Cancer Causes & Control.

[16]  Julie E. Chang,et al.  Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study , 2004, Hematological oncology.

[17]  A. Kong,et al.  In Vivo Pharmacokinetics and Regulation of Gene Expression Profiles by Isothiocyanate Sulforaphane in the Rat , 2004, Journal of Pharmacology and Experimental Therapeutics.

[18]  L. Tang,et al.  Selected isothiocyanates rapidly induce growth inhibition of cancer cells. , 2003, Molecular cancer therapeutics.

[19]  S. Mader,et al.  Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines , 2003, Leukemia.

[20]  R. Perez-soler,et al.  Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. , 2002, Molecular pharmacology.

[21]  Janet S. Lee,et al.  Mechanisms of action of arsenic trioxide. , 2002, Cancer research.

[22]  P. Hrelia,et al.  Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. , 2002, Carcinogenesis.

[23]  T. Shapiro,et al.  Quantitative determination of dithiocarbamates in human plasma, serum, erythrocytes and urine: pharmacokinetics of broccoli sprout isothiocyanates in humans. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[24]  J. Brooks,et al.  Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[25]  S. Soignet.  Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. , 2001, The oncologist.

[26]  K. Antman,et al.  Introduction: the history of arsenic trioxide in cancer therapy. , 2001, The oncologist.

[27]  Y. Y. Lee,et al.  Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. , 2000, Cancer research.

[28]  Pengfei Li,et al.  Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. , 2000, Cancer research.

[29]  J. Stanford,et al.  Fruit and vegetable intakes and prostate cancer risk. , 2000, Journal of the National Cancer Institute.

[30]  A. Porter,et al.  Signal transduction pathways regulated by arsenate and arsenite , 1999, Oncogene.

[31]  M. Kuo,et al.  Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells , 1999, British Journal of Cancer.

[32]  Jen-kun Lin,et al.  Involvement of reactive oxygen species and caspase 3 activation in arsenite‐induced apoptosis , 1998, Journal of cellular physiology.

[33]  P. Talalay,et al.  Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms. , 1994, Cancer research.

[34]  T. Chou,et al.  A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. , 1977, The Journal of biological chemistry.

[35]  Paul Talalay,et al.  Analysis of combined drug effects: a new look at a very old problem , 1983 .